Client News

Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma

AFYREN achieves “Responsible Care® Confirmed Diagnosis” certification and publishes its second sustainability report

Secarna Pharmaceuticals to Present New Data and Clinical Strategy for Lead Antisense Oligonucleotide Program SECN-15 at ASCO 2025

InflaRx to Participate in Upcoming Investor Conferences

ARTCLINE Establishes Scientific Advisory Board with Leading Experts from Nephrology, Intensive Care and Transfusion Medicine

Galimedix Therapeutics Publishes New Data in Peer-Reviewed International Journal of Molecular Sciences Demonstrating Disease-Modifying Capability of GAL-201 in Alzheimer’s Disease

Mallia Therapeutics Reports on Novel Therapeutic Approach for Treating Alopecia at the Annual Meeting of the European Hair Research Society (EHRS)

ReproNovo Raises $65 Million Series A Financing to Advance Phase 2 Clinical Trials of Novel Therapies in Reproductive Medicine and Women’s Health

Philikos Announces Initiation of Clinical Phase 1/2 Study with T-Guard® in Patients with Systemic Sclerosis

Journal of Critical Care Publishes Positive Results from Prespecified, Biomarker-guided Subgroup Analysis of AdrenoMed’s Phase II AdrenOSS-2 Trial in Septic Shock